Phalguni Deswal
LightNews LightNews
phalguniddw.bsky.social
Phalguni Deswal
@phalguniddw.bsky.social
20 followers 11 following 240 posts
Editor - Drug and Device World
Posts Replies Media Videos
phalguniddw.bsky.social
How can AI improve healthcare? By listening. Sciensus uses ambient AI to capture patient insights & give nurses more time for human care. Transforming the patient experience. #FutureOfHealthcare #AIforGood #NurseTech #Microsoft #PatientCentric
How ambient AI is capturing healthcare’s unheard data
The Sciensus team discusses how ambient AI captures patient sentiment to augment nurses, personalise care, and help keep patients healthier at home.
druganddeviceworld.com
February 9, 2026 at 2:08 PM
phalguniddw.bsky.social
The CAR T field is shifting to in vivo platforms that aim to make powerful cell therapies simpler, cheaper, and more accessible. Insights from Vyriad's Luke Russell. #CARTcell #immunotherapy #invivo #biotech #Vyriad #oncology #celltherpay
CAR T enters a new era of in vivo reprogramming of T cells
Vyriad's Luke Russell explores the technical and economic promise of in vivo CAR T-cell therapies.
druganddeviceworld.com
February 4, 2026 at 5:42 PM
phalguniddw.bsky.social
Cost shouldn’t be your first question in pharma supply chains, says Vector Labs’ Kum Ming Woo. Prioritize quality & availability, diversify geographically, and adopt stage-appropriate strategies.

#Interview #Expert #Pharma #SupplyChain #Biotech #Resilience #DrugDevelopment
Building resilient pharmaceutical supply chains in an era of disruption
Kum Ming Woo advises prioritizing supplier quality & availability over cost, emphasizing geographic diversification and stage-appropriate strategies.
druganddeviceworld.com
February 2, 2026 at 7:56 PM
phalguniddw.bsky.social
New study from Rapid Nexus challenges old view of nerve damage. Research shows targeting neuropathy can heal tissue once considered unsalvageable, helping patients avoid amputation.
#News #Diabetes #WoundCare #Neuropathy #MedicalInnovation #Research
Rapid Nexus study challenges neuropathy as the point of no return
New peer-reviewed research indicates nerve function is key to healing tissue once considered unsalvageable.
druganddeviceworld.com
January 27, 2026 at 7:56 PM
phalguniddw.bsky.social
In 2026, hospitals will split between running their own local AI and forming trusted partnerships, while certified AI medical devices gain major trust, says myTomorrow's Danny den Hamer.
#AIinHealthcare #HealthTech2026 #SaMD #LLM #DigitalHealth #Tends
Hospital of 2026: Local LLMs and AI Are Redefining Healthcare
myTomorrow’s Danny den Hamer identifies two trends for 2026: hospitals adopting local AI/trusted partners, and a rise in certified AI medical devices.
druganddeviceworld.com
January 26, 2026 at 12:38 PM
phalguniddw.bsky.social
Arkin Capital launches $100M Arkin Bio Ventures III to back transformative biotech companies. The fund takes a hands-on, science-driven approach as an active partner from day one.
#News #Interview #Biotech #VentureCapital #Therapeutics #DrugDiscovery
Arkin Bio Ventures III: $100 million fund for transformative therapies
Fund lead, Dr. Pini Orbach, talks about the fund targeting oncology, immunology, inflammation, rare diseases, and their aim to be an active partner from day one.
druganddeviceworld.com
January 22, 2026 at 3:45 PM
phalguniddw.bsky.social
ten23 health & BD partner to enable supply chain readiness for the BD Libertas wearable injector. The full-service solution aims to speed development of large-volume, self-administered therapies.

#News #SupplyChain #WearableInjector #Biotech #Pharma #DrugDelivery #Partnership
Becton Dickinson and ten23 partner on wearable injector supply
Partnership will support the supply for Becton, Dickinson and Company's self-administered therapies with a ready-to-use, scalable platform.
druganddeviceworld.com
January 21, 2026 at 6:03 PM
phalguniddw.bsky.social
Genesipre’s gene therapy GENE202 has received Orphan Drug Designation for methylmalonic acidemia (MMA), a rare pediatric disease.
#News #GeneTherapy #RareDisease #OrphanDrug #MMA #Biotech
Genesipre’s rare disease therapy gets orphan drug status in the US and Europe
The gene therapy is being developed to treat a rare pediatric metabolic disease, methylmalonic acidemia (MMA).
druganddeviceworld.com
January 21, 2026 at 5:39 PM
phalguniddw.bsky.social
Brainomix's AI imaging tech will serve as a co-primary endpoint in Boehringer Ingelheim's Phase 3 DROP-FPF trial for pulmonary fibrosis—a first for ILD studies. #AI #News #ClinicalTrials #PulmonaryFibrosis #MedicalImaging #Brainomix
Boehringer picks AI imaging tech as co-primary endpoint for IPF trial
Brainomix's e-Lung AI will provide quantitative imaging biomarkers as a co-primary endpoint in Boehringer Ingelheim's Phase III DROP-FPF study.
druganddeviceworld.com
January 21, 2026 at 5:09 PM
phalguniddw.bsky.social
VCU researchers awarded $1.8M DoD grant to develop a novel engineered NK cell therapy targeting incurable, advanced prostate cancer (CRPC).
#News #ProstateCancer #Immunotherapy #CRPC #CellTherapy #NKcells #IL24 #DoDgrant
VCU researchers win $1.8 million US DoD grant for cancer therapy
The US Department of Defense (DoD) grant funds engineered NK cell therapy for resistant prostate cancer.
druganddeviceworld.com
January 21, 2026 at 4:35 PM
phalguniddw.bsky.social
Abbott’s $21B acquisition of Exact Sciences signals a new era in cancer detection. We analyze the high-stakes MCED market, pivotal FDA decisions, and the reimbursement battle ahead with Gabelli Funds’ Elena Meng.

#MCED #cancerscreening #Abbott #ExactSciences #healthcareinvesting #biotech
The New Gold Rush: High-stakes race for multi-cancer blood tests
Abbott's $21 billion Exact Sciences buyout sets stage for high-stakes MCED battle, Elena Ming talks about the major players in the sector and hurdles.
druganddeviceworld.com
January 16, 2026 at 10:30 AM
phalguniddw.bsky.social
FDA approves Stereotaxis MAGiC robotic ablation catheter. A breakthrough for treating complex heart arrhythmias with precise magnetic navigation.
#News #Stereotaxis #FDAapproval #cardiology #robotics #arrhythmia #healthtech
Stereotaxis MAGiC catheter cleared by FDA for robotic heart ablation
The US FDA approves Stereotaxis' robotic magnetic navigation catheter for complex cardiac arrhythmia procedures.
druganddeviceworld.com
January 15, 2026 at 10:42 AM
phalguniddw.bsky.social
Clinical trial start-up delays are rising due to complex protocols & contract bottlenecks. ICON survey data reveals 55% of sites take 5+ months to activate. Solutions require site-centricity & smarter tech.
#Interview #ClinicalTrials #StudyStartup #SiteCentricity #ICON #DrugDevelopment
Examining the growing delays in clinical trial start-up
ICON exec discusses the increasing timeframe from site selection to full activation, including the issues contributing to the delay and measures to address them.
druganddeviceworld.com
January 15, 2026 at 10:09 AM
phalguniddw.bsky.social
EA Pharma (Eisai) starts Phase III trial in Japan for evenamide, a novel glutamate modulator for schizophrenia.
The drug was licensed as part of a €117M deal with Newron Pharmaceuticals.

#News #Schizophrenia #ClinicalTrial #MentalHealth #Biotech #Eisai #Evenamide
Eisai subsidiary starts Phase III trial for Schizophrenia drug in Japan
EA Pharma initiates a pivotal study of the novel glutamate modulator, evenamide, for treatment-resistant schizophrenia in Japan.
druganddeviceworld.com
January 10, 2026 at 3:05 PM
phalguniddw.bsky.social
Canopy secures $22M Series B to expand its connected safety platform for combating workplace violence and modernize hospital operations with location intelligence.
#News #HealthTech #SeriesB #WorkplaceSafety #Innovation #LocationIntelligence
Canopy raises $22 million for healthcare safety platform
The Series B funding is expected to finance the expansion of Canopy’s connected safety platform across US health systems.
druganddeviceworld.com
January 10, 2026 at 2:19 PM
phalguniddw.bsky.social
New #research by endogene.bio reveals why #endometriosis treatments often fail. The study identifies molecular subgroups & predicts drug response, suggesting non-invasive monitoring via menstrual blood could guide precision therapy.
#News #WomensHealth #PrecisionMedicine #ClinicalTrials
Endometriosis study uncovers molecular subgroups to guide trials
Endogene.bio’s research reveals how single-cell analysis predicts drug efficacy, enabling targeted treatments for endometriosis subgroups.
druganddeviceworld.com
January 7, 2026 at 5:53 PM
phalguniddw.bsky.social
Gallop’s LYT-200 shows 13.2-month median survival in late-line AML at #ASH2025—far exceeding historic benchmarks. The anti-galectin-9 antibody combines strong efficacy with a clean safety profile.

#News #Leukemia #Oncology #Biotech #ClinicalTrials #AML
ASH25: Gallop’s LYT-200 shows unprecedented survival in AML
The company’s execs talk about the striking efficacy and safety signals seen in Phase I data, the science behind the molecule, and their vision for transforming AML therapy.
druganddeviceworld.com
January 6, 2026 at 2:37 PM
phalguniddw.bsky.social
Healing chronic wounds twice as fast? SweetBio’s honey-based biomaterial is tackling the hidden amputation crisis, blending ancient remedies with cutting-edge science. #News #WoundCare #Diabetes #MedTech #Innovation #Biomaterials #DiabeticFootUlcer
SweetBio’s honey-based bandage saving limbs and closing wounds
The US-based company’s CEO talks about how novel biomaterial tackles the hidden crisis of chronic wounds, blending ancient remedies with modern science to prevent amputations.
druganddeviceworld.com
December 26, 2025 at 6:12 PM
phalguniddw.bsky.social
CNS Pharmaceuticals re-engineers old chemotherapies to cross the blood-brain barrier, targeting aggressive glioblastoma. Dr. Sandra Silberman explains their "back to the future" strategy and two promising drugs. #BrainCancer #Glioblastoma #Biotech #Oncology #BloodBrainBarrier #CNSPharmaceuticals
Old becomes New: CNS Pharma’s quest to tackle brain cancers
CNS Pharmaceuticals’ CMO explains how they are re-engineering old chemotherapies to penetrate the brain, aiming for a breakthrough in treating aggressive glioblastoma.
druganddeviceworld.com
December 24, 2025 at 11:37 AM
phalguniddw.bsky.social
New data at #ASH2025 show Secure Bio's Copiktra's (duvelisib) consistent efficacy in heavily pretreated PTCL, with strong signal in AITL informing Phase 3 TERZO trial in nTFHL.
#news #interview #lymphoma #clinicaltrials #oncology
Secura Bio’s Copiktra PTCL data shines at ASH 2025 
The company’s exec talks about how new analyses bolster the case for Copiktra in tough-to-treat lymphomas, informing a pivotal Phase III trial strategy.
druganddeviceworld.com
December 23, 2025 at 10:32 AM
phalguniddw.bsky.social
FoRx Therapeutics raises $50M Series A to advance clinical trial of FORX-428, a PARG inhibitor for PARP-resistant cancers. Initial data expected mid-2026.
#News #Biotech #Funding #Oncology #ClinicalTrials #PARG
FoRx secures $50 million to advance PARG inhibitor
Swiss biotech raises Series A financing to advance PARG inhibitor FORX-428, with initial clinical data expected in 2026.
druganddeviceworld.com
December 18, 2025 at 9:23 PM
phalguniddw.bsky.social
CTMC’s global alliance partners with Brazil’s Einstein Hospital to democratize cell therapy. CTMC’s Amy Hay details a partnership model to share knowledge and expand cell therapy access worldwide.
#News #Interview #CellTherapy #GlobalHealth #MedicalInnovation
CTMC maps out plans to democratize cell therapy
CTMC’s Amy Hay details a partnership model to share knowledge and expand cell therapy access worldwide, starting with Brazil.
druganddeviceworld.com
December 17, 2025 at 10:04 AM
phalguniddw.bsky.social
FDA approves Cardamyst, the Milestone Pharmaceuticals’ self-administered nasal spray for PSVT. A rapid at-home treatment for sudden rapid heart episodes, available in 2026.
#News #PSVT #CARDAMYST #FDAapproval #HeartHealth #MedicalNews
Milestone Pharma wins FDA nod for self-administered nasal spray for PSVT
The at-home treatment is designed to manage acute symptomatic episodes outside of emergency healthcare settings.
druganddeviceworld.com
December 16, 2025 at 7:26 PM
phalguniddw.bsky.social
Dr. Margaret Kalmeta, CEO of Rapid Nexus, discusses the first device cleared to treat the tissue around chronic wounds, aiming to prevent amputations. Read more for company's pipeline and future plans
#MedTech #WoundCare #FDA #Diabetes #Innovation #Interview #News
Rapid Nexus charts a new path for chronic wounds
Dr. Margaret Kalmeta, CEO of Rapid Nexus, discusses the first device cleared to treat the tissue around chronic wounds and the company’s pipeline.
druganddeviceworld.com
December 15, 2025 at 8:55 AM
phalguniddw.bsky.social
New data from Agendia's FLEX study at #SABCS2025 shows genomic signatures like MammaPrint can guide chemo choices & identify benefit in elderly patients.
#news #breastcancer #precisionmedicine #realworldevidence
SABCS25: Agendia’s genomic testing guides breast cancer care 
Agendia’s VP of clinical development notes that new FLEX study data show genomic signatures predict chemotherapy benefit, improving personalized treatment for early breast cancer.
druganddeviceworld.com
December 12, 2025 at 8:09 PM